Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Lowers Position in UnitedHealth Group Incorporated $UNH

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA cut its stake in shares of UnitedHealth Group Incorporated (NYSE:UNH - Free Report) by 71.3% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 835 shares of the healthcare conglomerate's stock after selling 2,076 shares during the period. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA's holdings in UnitedHealth Group were worth $260,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Nabity Jensen Investment Management Inc boosted its stake in shares of UnitedHealth Group by 0.9% in the first quarter. Nabity Jensen Investment Management Inc now owns 2,760 shares of the healthcare conglomerate's stock worth $1,446,000 after acquiring an additional 24 shares during the period. Atlantic Edge Private Wealth Management LLC boosted its stake in shares of UnitedHealth Group by 8.9% in the first quarter. Atlantic Edge Private Wealth Management LLC now owns 305 shares of the healthcare conglomerate's stock worth $160,000 after acquiring an additional 25 shares during the period. HHM Wealth Advisors LLC boosted its stake in shares of UnitedHealth Group by 0.9% in the first quarter. HHM Wealth Advisors LLC now owns 2,947 shares of the healthcare conglomerate's stock worth $1,544,000 after acquiring an additional 26 shares during the period. Brogan Financial Inc. boosted its stake in shares of UnitedHealth Group by 3.4% in the first quarter. Brogan Financial Inc. now owns 819 shares of the healthcare conglomerate's stock worth $429,000 after acquiring an additional 27 shares during the period. Finally, West Wealth Group LLC lifted its position in shares of UnitedHealth Group by 3.2% in the first quarter. West Wealth Group LLC now owns 882 shares of the healthcare conglomerate's stock worth $462,000 after buying an additional 27 shares in the last quarter. 87.86% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms recently commented on UNH. Oppenheimer decreased their target price on UnitedHealth Group from $400.00 to $325.00 and set an "outperform" rating on the stock in a research report on Wednesday, July 30th. Zacks Research upgraded UnitedHealth Group from a "strong sell" rating to a "hold" rating in a research report on Monday, October 6th. JPMorgan Chase & Co. boosted their price objective on UnitedHealth Group from $310.00 to $425.00 and gave the stock an "overweight" rating in a research note on Thursday, October 9th. Sanford C. Bernstein boosted their price objective on UnitedHealth Group from $379.00 to $433.00 and gave the stock an "outperform" rating in a research note on Wednesday, October 8th. Finally, KeyCorp boosted their price objective on UnitedHealth Group from $350.00 to $400.00 and gave the stock an "overweight" rating in a research note on Wednesday, October 8th. Eighteen investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and four have assigned a Sell rating to the stock. According to data from MarketBeat.com, UnitedHealth Group currently has a consensus rating of "Hold" and an average target price of $385.13.

UnitedHealth Group Trading Down 0.3%

Shares of NYSE UNH opened at $360.48 on Friday. The company has a debt-to-equity ratio of 0.73, a quick ratio of 0.85 and a current ratio of 0.85. The business's 50 day moving average price is $337.26 and its 200-day moving average price is $340.29. UnitedHealth Group Incorporated has a fifty-two week low of $234.60 and a fifty-two week high of $630.73. The company has a market cap of $326.48 billion, a price-to-earnings ratio of 15.62, a PEG ratio of 2.34 and a beta of 0.47.

UnitedHealth Group (NYSE:UNH - Get Free Report) last issued its quarterly earnings results on Tuesday, July 29th. The healthcare conglomerate reported $4.08 earnings per share for the quarter, missing the consensus estimate of $4.45 by ($0.37). UnitedHealth Group had a return on equity of 23.32% and a net margin of 5.04%.The business had revenue of $111.62 billion during the quarter, compared to analysts' expectations of $111.75 billion. During the same quarter in the previous year, the company posted $6.80 earnings per share. The company's quarterly revenue was up 12.9% compared to the same quarter last year. UnitedHealth Group has set its FY 2025 guidance at 16.000- EPS. On average, sell-side analysts expect that UnitedHealth Group Incorporated will post 29.54 earnings per share for the current year.

UnitedHealth Group Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 23rd. Stockholders of record on Monday, September 15th were issued a $2.21 dividend. This represents a $8.84 annualized dividend and a dividend yield of 2.5%. The ex-dividend date was Monday, September 15th. UnitedHealth Group's dividend payout ratio is presently 38.30%.

UnitedHealth Group Profile

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.